Loading…
Indian branded-generics and consumer-healthcare maker known for OTC brands like Manforce and Prega News, plus prescription drugs.
Indian branded-generics and consumer-healthcare maker known for OTC brands like Manforce and Prega News, plus prescription drugs.
Sells prescription drugs through a very large force of sales representatives who visit doctors and chemists, and consumer brands such as Manforce condoms and Prega News pregnancy kits through pharmacies and shops. Most sales are in India. The 2024 purchase of Bharat Serums and Vaccines added women's health and critical-care products. The Juneja family are the promoters.
In one line: India's OTC-and-generics hybrid, part Cipla part J&J consumer.
Moat: narrow (brand, distribution). Strong consumer brand recall and one of India's largest pharma field forces.
Headquarters: New Delhi, India · Founded: 1995 · Employees: 27,000
Size Mankind Pharma (MANKIND.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $11.1B, the 111th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹2,540 on 6 Nov 2026.
Performance Over six months the shares gained 6.9%, against +3.8% for the median peer and 0.0% for the India market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 13.3% over the last twelve months (peer median +18.2%); the operating margin is 20.6% (peer median 14.4%).
Valuation It trades at 43.2× forward earnings against a peer median of 30.9× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.6 points above its cost of capital (10.7% WACC).
Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹154B | ₹143B | ₹122B | ₹103B | ₹87.4B |
| Revenue growth | — | +17% | +19% | +17% | — |
| Gross profit | ₹67.9B | ₹56.4B | ₹50.4B | ₹41.2B | ₹33.9B |
| EBITDA | ₹40.8B | ₹36.6B | ₹31.0B | ₹25.6B | ₹19.4B |
| Net income | ₹22.4B | ₹19.1B | ₹19.9B | ₹19.1B | ₹12.8B |
| Free cash flow | n/a | ₹18.9B | ₹19.1B | ₹18.4B | ₹9.96B |
| Capital expenditure | n/a | ₹7.37B | ₹5.31B | ₹3.89B | ₹8.32B |
| Total debt | ₹54.2B | ₹63.1B | ₹85.1B | ₹2.07B | ₹1.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Mankind Pharma MANKIND.NS | $11.1B | +7% | +13% | 21% | 43.2× | 27.6% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $47.3B | +1% | +12% | 23% | 35.4× | 28.4% |
| Cipla CIPLA.NS | $12.1B | +4% | -1% | 13% | 29.0× | 28.2% |
| Zydus Lifesciences ZYDUSLIFE.NS | $12.7B | +27% | +24% | 17% | 29.8× | n/a |
| Lupin LUPIN.NS | $9.65B | -19% | +24% | 24% | 20.9× | 8.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | $19.1B | +9% | +42% | 22% | 72.2× | 37.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MANKIND.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.6% | +4.2% | 10th lowest of 21 |
| 6-month return | +6.9% | +3.8% | 9th highest of 21 |
| Distance from 52-week high | -3.9% | -13.6% | 3rd highest of 21 |
| Revenue growth (TTM) | +13.3% | +18.2% | 7th lowest of 20 |
| Operating margin | 20.6% | 14.4% | 6th highest of 20 |
| Forward P/E | 43.2× | 30.9× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 27.6% | 25.8% | 7th most demanding of 14 |
| Growth delivered (Del g) | +18.1% | +7.4% | 3rd highest of 14 |
| Hurdle (Req g minus delivered) | +9.5 pp | -2.5 pp | 7th most demanding of 14 |
| ROIC minus cost of capital | +0.6 pp | +1.6 pp | 8th lowest of 18 |
| EV / EBITDA | 26.5× | 20.3× | 4th most expensive of 9 |
| Net debt / EBITDA | 0.7× | 0.5× | 6th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mankind Pharma MANKIND.NS | India | $11.1B | +7% | +13% | 21% | 43.2× | 27.6% | +18.1% |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 71.3× | 56.4% | +15.0% |
| Pharmaron Beijing 300759.SZ | China | $11.3B | +57% | +18% | 14% | 42.3× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $10.2B | -38% | +42% | -25% | n/a | n/a | n/a |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.1B | +5% | -4% | 9% | 31.8× | 30.1% | +12.1% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $12.3B | -5% | -19% | 19% | 42.1× | 25.8% | +6.8% |
| Recordati REC.MI | Italy | $12.3B | +3% | +9% | 30% | 16.7× | 1.9% | +12.6% |
| Spyre Therapeutics SYRE | United States | $9.86B | +38% | n/a | n/a | n/a | n/a | n/a |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.7B | +27% | +24% | 17% | 29.8× | n/a | n/a |
| Sbp 1177.HK | Hong Kong | $12.7B | +4% | +15% | 30% | 18.3× | -5.4% | +5.4% |
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 79.5× | n/a | n/a |
| Laurus Labs LAURUSLABS.NS | India | $13.3B | +94% | +23% | 24% | 77.0× | 50.9% | +7.3% |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 30.9× | 50.3% | +426.7% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | n/a | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.9B | 0% | +44% | -38% | 1,255.9× | 56.2% | +33.7% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $8.70B | -5% | +8% | 6% | 17.0× | 4.1% | +6.6% |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 48.4× | 47.5% | +10.0% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.48B | -7% | +9% | 3% | 6.6× | -10.3% | +7.4% |
| Yunnan Baiyao 000538.SZ | China | $14.7B | +4% | +5% | 11% | 18.0× | -0.5% | +4.7% |
| Ipsen IPN.PA | France | $14.7B | -4% | +14% | 30% | 10.9× | -7.3% | +7.2% |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $8.19B | +22% | +24% | 17% | 29.2× | n/a | n/a |